Leerink analyst Andrew Berens initiated coverage of OnKure Therapeutics (OKUR) with an Outperform rating and $33 price target The firm notes OnKure is leveraging an expertise in targeted drug discovery to develop a platform of highly targeted PI3Kalpha agents that are more potent at relevant oncogenic mutations, while sparing normal tissues. Leerink views the company’s lead asset OKI-219 as a potential blockbuster+ agent, targeting H1047R mutations in HR+ breast cancer. Its peak sales for ‘219 in breast cancer are $1.4B, which represents $30/share in the firm’s model.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKUR:
- OnKure Therapeutics Reports Strategic Merger and Financial Updates
- OnKure Therapeutics Faces Post-Merger Hurdles: Integration Challenges and Talent Competition Threaten Growth
- OnKure files to sell 2.94M shares of Class A common stock for holders
- OnKure Therapeutics assumed with a Buy at H.C. Wainwright
- OnKure Therapeutics initiated with an Outperform at LifeSci Capital